The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease

About this trial

Last updated 14 years ago

Study ID

NottinghamNHST1

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

Accepting

18+ Years

All Sexes

Trial Timing

Ended 16 years ago

What is this trial about?

The principal purpose of this study is to determine whether increased intakes of n-3 polyunsaturated (omega-3) fatty acids will reduce the amount of fat stored in the liver in patients with non-alcoholic fatty liver disease.

What are the participation requirements?

Inclusion Criteria

1. Age greater than 18 years

2. Liver biopsy diagnosis of NAFLD

Exclusion Criteria

1. Excessive alcohol intake - > 21 units per week in men and > 14 in women

2. A further liver disease diagnosis

3. Poorly controlled diabetes - HbA1c > 8.0%, or use of insulin sensitisers

4. Pregnancy

5. Cirrhosis

6. Contraindications to MR scanning - pacemaker or metallic foreign body etc.

7. Changes in the dose or initiation of lipid altering medication within the preceding three months, such as statins, fibrates or systemic steroids

8. Use of n-3 PUFA supplements within the prior 4 months, an adequate washout period

9. Significant co-morbid inflammatory illnesses as determined by research team